Lam Research Corporation vs Teladoc Health Inc — how do they compare? Lam Research Corporation trades at $319.3 (market cap $401.19B), while Teladoc Health Inc trades at $5.78 (market cap $1.01B). The key difference: Lam Research Corporation is far larger — about 397.2× Teladoc Health Inc's market cap, and Lam Research Corporation pays a 0.41% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lam Research Corporation for 60 Days and Teladoc Health Inc for 39 Days on average.
| LRCX | TDOC | |
|---|---|---|
Market Cap | $401.19B | $1.01B |
Volume | 8,960,892 | 4,668,477 |
Sector | Technology | Health |
52-Week High | $433.33 | $9.72 |
52-Week Low | $131.37 | $4.47 |
Typical Hold Time | 60 Days | 39 Days |
Enterprise Value | $399.35B | $1.27B |
Dividend Yield | 0.41% | — |
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) is trading at $319.42, down 3.06% on the day, amid a broader bearish technical signal. The stock exhibits strong fundamentals with revenue of $18.44B in 2025 and a net income margin of 31.27%, supported by three consecutive quarterly earnings beats. Analyst consensus is overwhelmingly bullish with a 78% buy rating and a $375.68 price target, citing AI-driven demand for semiconductor equipment. Recent news highlights the company's strategic positioning in AI infrastructure and margin expansion targets.
The outlook for LRCX is positive, driven by robust earnings growth and expanding profitability, though valuation multiples remain elevated. Key risks include cyclical semiconductor demand and competitive pressures. With strong institutional support and a clear growth trajectory, the stock presents a compelling opportunity for long-term investors, contingent on sustained execution in a dynamic market.
Teladoc Health (TDOC) trades at $5.67, showing modest daily gains but remains near multi-year lows with a bearish technical outlook. The company maintains strong revenue around $2.5B annually but continues to report net losses, with a -7.13% net margin in 2026. Recent management changes include the appointment of a new CFO, while analyst sentiment remains cautious despite a consensus price target of $8.83 representing 56% upside potential.
TDOC presents a high-risk opportunity with significant upside potential if the company can achieve profitability turnaround. The stock trades at discounted valuations (P/S 0.4x, P/B 0.77x) but faces execution risks from ongoing losses, BetterHelp segment challenges, and potential legal investigations. Free cash flow generation and integrated care growth provide stabilization, though sustained profitability remains the key catalyst needed for sustained recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →